摘要
通过分析Ki67在乳腺癌表达水平与临床病理特征相关性以及研究其在术后新辅助化疗前后的变化,探讨Ki67标记指数在乳腺癌治疗中的临床意义。采取免疫组化法(SP法)检测2012年后该院的246例乳腺癌患者的336例乳腺癌病理组织中Ki67的阳性表达情况,其中包括90例患者新辅助化疗前后的组织标本。Ki67阳性比例为67.5%(166/246),Ki67的表达与肿瘤大小、淋巴结转移、组织细胞学分级和人表皮生长因子受体-2成正相关(为P<0.05或P<0.01),与年龄、雌激素受体、孕激素受体表达成负相关(均为P<0.01),与TNM分期无明显相关性;Ki67在新辅助化疗前后的表达变化值与化疗疗效明显相关(P<0.01),新辅助化疗效果越好,Ki67下降越明显。Ki67阳性表达与乳腺癌的临床病理特征有密切的相关性,对乳腺癌的早期诊断、治疗与预后有指导意义,另外术后新辅助化疗影响Ki67的表达,Ki67对预测新辅助化疗的疗效有重要意义,但其是否可以作为乳腺癌诊断预后及新辅助化疗疗效的可靠指标仍需进一步研究。
This study aimed to explore the significance of Ki67 labeling index in the treatment and prognosis of breast cancer by analyzing the correlation between Ki67 level and clinical pathological characteristics and its change of level after neoadjuvant chemotherapy in patients who had been subjected to surgical operation. Immunohistochemical method （SP） was adapted to de- termine the positive rate of Ki67 in the cancer tissues from 336 cases of patients with breast cancer who admitted to our hospital since 2012. In addition, 90 cases were examined before and after neoadjuvant chemotherapy. The results showed that Ki67 pos- itive ratio was 67.5 % （166/246）, and the positive rate was positively correlated with tumor size, lymph node metastasis, his- tologieal grading and human epidermal growth factor receptor-2 （P〈0. 05 or P〈0.01） but not correlated with TNM stage. In contrast, Ki67 positivity was negatively correlated with age, estrogen receptor and progesterone receptor （P〈0.01）. Ki67 lev- el was decreased after chemotherapy and was significantly associated with the efficacy of treatment （P〈0.01）, the more effi- cient of the therapy, the lower the Ki67 level. Altogether, these findings indicate that there is a close correlation between the positive expression of Ki67 and the occurrence and development of breast cancer, suggesting that Ki67 may participate the whole course of carcinogenesis of breast cancer. The test of Ki67 might be valuable for early diagnosis, treatment and prognosis of breast cancer; however, it should not be taken as an absolute index for estimating the survival rate of patients with breast cancer.
出处
《现代免疫学》
CAS
CSCD
北大核心
2015年第6期492-496,共5页
Current Immunology
关键词
KI67
乳腺癌
新辅助化疗
免疫组化方法
Ki67
breast cancer
neoadjuvant chemotherapy
immunohistochemistry
作者简介
林秀欣（1973-），女，江门市人，本科，副主任医师，主研方向：恶性肿瘤的综合治疗,（E-mail：linxiuxin572@163．com）
